Structural Studies Of Thyroid Peroxidase, An Autoantigen In Autoimmune Thyroid Disease
Funder
National Health and Medical Research Council
Funding Amount
$386,423.00
Summary
This proposal is aimed at determining the three dimensional structure of Thyroid Peroxidase, a protein found in the human thyroid gland that is important in the production of the hormone thyroxine. Thyroxine is involved in controlling the rate of metabolic processes in the body and influencing physical development.
A Novel Approach To Streamlining The Diagnosis Of Primary Aldosteronism
Funder
National Health and Medical Research Council
Funding Amount
$269,463.00
Summary
This study will assess a new clinical test used to diagnose a potentially curable form of high blood pressure called primary aldosteronism (PA). If successful, the test will greatly streamline and simplify the diagnosis of this condition, with the potential for enormous cost savings and a markedly increased rate of diagnosis of patients with PA who can then benefit from optimal treatment and improved quality of life.
Understanding The Control Of Brain Development And Endocrine Function Through Central Regulation Of Gene Transcription
Funder
National Health and Medical Research Council
Funding Amount
$624,846.00
Summary
Intellectual disability affects about 2% of the Australian population. The identification of genes underlying a number of intellectual disability disorders has brought about great clinical advances. However, our knowledge of how these genes influence processes of brain development and are important for intelligence is very limited. We propose to study the function of PHF6, the gene mutated in the Börjeson-Forssman-Lehmann intellectual disability syndrome, during brain development.
SOFT And TEXT Premenopausal Randomised Adjuvant Endocrine Breast Cancer Trials.
Funder
National Health and Medical Research Council
Funding Amount
$722,380.00
Summary
SOFT and TEXT trials enrolled premenopausal women with hormone-sensitive early breast cancer to assess if post-operative hormone treatment that included ovarian function suppression plus tamoxifen, or an aromatase inhibitor exemestane, could improve outcomes. Initial results indicate fewer breast cancer recurrences with the treatment combination of ovarian suppression plus exemestane as compared with tamoxifen, and follow-up of women in these trials can show if overall survival can be improved.
Endocrine Therapy Tolerance As A Cancer Cell Survival Mechanism For Late Recurring Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$450,083.00
Summary
~25% of breast cancer deaths are attributable to cancers that have failed endocrine therapy and recur >5 years after primary diagnosis. These cancers are not well understood because their long latency makes them difficult to study. We have new models of this disease that identify a “therapy tolerant” population, and this is likely to re-emerge to cause late recurrence. Our work could potentially identify new biological tests and therapeutic strategies to treat late recurring breast cancer.
Randomised Phase II Trial Of Neoadjuvant Chemotherapy +/- Concurrent Aromatase Inhibitor Endocrine Therapy To Down-stage Large Oestrogen Receptor Positive Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$2,302,496.00
Summary
Women diagnosed with large oestrogen receptor positive breast cancer are often treated with chemotherapy before surgery to reduce the size of the cancer, while treatment to lower oestrogen levels is given after surgery. This trial is studying if combining chemotherapy with oestrogen lowering treatment before surgery will better shrink the cancer which can improve the surgery options.
Estrogen Therapy For Castrate Resistant Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$531,690.00
Summary
Withdrawal of male hormones in men with prostate cancer is effective therapeutically because it causes cell death in most of the tumour. However the remaining cells (called castrate resistant cells), give rise to recurrent disease that inevitably kills the patient. This project aims to test if our compound will kill these cells and prevent recurrence or if it has any benefit for the patients who have incurable disease.
The Older Australian Twins Study (OATS) Of Healthy Brain Ageing And Age-related Neurocognitive Disorders
Funder
National Health and Medical Research Council
Funding Amount
$940,960.00
Summary
Ageing is associated with cognitive decline and dementia. It is still not completely understood what relative contributions genes and environment play in these. This project is an extension of the Older Australian Twins Study to examine genetic and environmental factors associated with late life brain changes and dementia, and will establish an internationally significant cohort for novel discovery.
Cardiovascular disease is the biggest killer in Australia. It describes diseases of the heart and blood vessels including heart attack and stroke. The risk of developing these diseases is affected by our diet and lifestyle and also by our genetic makeup that we inherit. In this project we are aiming to identify the specific heritable genetic differences between individuals that put us at greater risk of cardiovascular disease. We are studying large families from the Busselton Health Study.
Novel Molecular Markers Of Lung Cancer Risk And Survival
Funder
National Health and Medical Research Council
Funding Amount
$824,765.00
Summary
Lung cancer remains the most lethal cancer worldwide, yet little is known of the risk factors beyond that of tobacco smoking and certain occupational exposures. We have assembled a large international consortium comprising 24 cohort studies and over 10,000 to validate associations between B-vitamins and lung cancer risk particularly in never and former smokers. We propose to expand this study and use the Melbourne Collaborative Cohort Study and the rest of the consortium to identify novel biomar ....Lung cancer remains the most lethal cancer worldwide, yet little is known of the risk factors beyond that of tobacco smoking and certain occupational exposures. We have assembled a large international consortium comprising 24 cohort studies and over 10,000 to validate associations between B-vitamins and lung cancer risk particularly in never and former smokers. We propose to expand this study and use the Melbourne Collaborative Cohort Study and the rest of the consortium to identify novel biomarkers of risk and survival.Read moreRead less